Reta GLP-1 (Dry) 12mg

Reta GLP-1 (Dry Powder Formulation) Triple-Action Incretin Therapy in a Compounded, Advanced Format

Reta GLP-1 is an investigational triple-action peptide that targets GLP-1, GIP, and glucagon receptors, offering a next-generation approach to weight loss, metabolic optimization, and glycemic control. This dry powder formulation is compounded for reconstitution, providing increased shelf stability and customizable dosing for practices seeking cutting-edge, personalized protocols.

By activating three metabolic pathways simultaneously, Retatrutide has shown the potential for unprecedented efficacy in weight reduction and metabolic regulation—surpassing the performance of dual or single agonists in early studies.

Why Consider Reta GLP-1 (Dry Powder)?

• Triple-action mechanism: Simultaneously activates GLP-1, GIP, and glucagon receptors for enhanced metabolic impact
• Increased fat burning potential: Glucagon receptor activation may support thermogenesis and energy expenditure
• Flexible dosing: Compounded for patient-specific titration to minimize side effects and optimize results
• Dry powder stability: Longer shelf life and convenient reconstitution for clinical or at-home administration
• Next-generation therapy: Designed for practices at the forefront of metabolic and weight loss medicine

Potential Clinical Benefits:

• Significant weight loss through appetite suppression and increased energy expenditure
• Enhanced insulin sensitivity and glycemic control
• Reduced food cravings and improved satiety
• Suitable for patients with obesity, metabolic dysfunction, or prediabetes under supervised care

Formulation: Dry powder for reconstitution; subcutaneous weekly injection

Availability: Compounded per patient-specific prescription

Disclaimer: Retatrutide is a research peptide. It is not FDA-approved and is currently being studied for its safety and efficacy. This product is intended for research or investigational use only under the supervision of a licensed healthcare professional.